Opinion|Videos|March 27, 2025

Use and Sequencing of Novel Treatments in NMIBC

Author(s)Chad A. Reichard, MD , Karim Chamie, MD, MSHS , R. Jonathan Henderson, MD

Experts discuss where they are using FDA-approved treatments for bacille Calmette-Guérin (BCG)–unresponsive patients in their practice, how they choose between these treatments, and how these advances have impacted the timing of radical cystectomy for patients.

Episodes in this series

EP. 1 Standard of Care and Intravesical Chemotherapy in NMIBC

EP. 1 Standard of Care and Intravesical Chemotherapy in NMIBC

EP. 2 BCG for treatment of NMIBC

EP. 2 BCG for treatment of NMIBC

EP. 3 Cystectomy in NMIBC

EP. 3 Cystectomy in NMIBC

EP. 4 New Intravesical Delivery Systems and TAR-200 in NMIBC

EP. 4 New Intravesical Delivery Systems and TAR-200 in NMIBC

EP. 5 TAR-200 Efficacy and Safety in High-Risk BCG- Unresponsive NMIBC (SunRISe-1)

EP. 5 TAR-200 Efficacy and Safety in High-Risk BCG- Unresponsive NMIBC (SunRISe-1)

EP. 6 TAR-200 Clinical Development Program in NMIBC

EP. 6 TAR-200 Clinical Development Program in NMIBC

EP. 7 Other Investigational Drug Delivery Systems in NMIBC

EP. 7 Other Investigational Drug Delivery Systems in NMIBC

EP. 8 Cretostimogene Grenadenorepvec and Integration of Novel Therapies in High-Risk BCG-Unresponsive NMIBC

EP. 8 Cretostimogene Grenadenorepvec and Integration of Novel Therapies in High-Risk BCG-Unresponsive NMIBC

EP. 9 FDA-Approved Treatments for BCG-Unresponsive NMIBC

EP. 9 FDA-Approved Treatments for BCG-Unresponsive NMIBC

EP. 10 Use and Sequencing of Novel Treatments in NMIBC

EP. 10 Use and Sequencing of Novel Treatments in NMIBC

EP. 11 Communication of Treatment Options for High-Risk NMIBC

EP. 11 Communication of Treatment Options for High-Risk NMIBC

EP. 12 Checkpoint Inhibitors for Treatment of NMIBC

EP. 12 Checkpoint Inhibitors for Treatment of NMIBC

EP. 13 Unmet Needs in NMIBC

EP. 13 Unmet Needs in NMIBC

EP. 14 Operationalizing TAR-200 and Other Delivery Systems in Practice

EP. 14 Operationalizing TAR-200 and Other Delivery Systems in Practice

EP. 15 Patient Communication and Treatment Adherence in NMIBC

EP. 15 Patient Communication and Treatment Adherence in NMIBC

EP. 16 Uptake of New Treatments in Urology Practice

EP. 16 Uptake of New Treatments in Urology Practice

EP. 17 Final Thoughts and Clinical Trials in NMIBC

EP. 17 Final Thoughts and Clinical Trials in NMIBC

Video content above is prompted by the following:

Where are you using these treatments in your practice, and how do you choose between them for BCG-unresponsive patients?
How have these advances changed the timing of radical cystectomy for patients?

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Related Content

Managing BPH Before Prostate Radiotherapy: Options Compared

ByAurelie Garant, MD,Daniel Welchons, MD

September 14th 2026

Patient Selection and Partnership in Prostate Radiotherapy Spacing

ByAurelie Garant, MD,Daniel Welchons, MD

September 14th 2026

Referral Pathways and Unmet Needs in Perioperative MIBC Care

ByJoshua J. Meeks, MD, PhD

September 4th 2026

MIBC Treatment Timeline and Skin Toxicity: What Urologists Should Know

ByJoshua J. Meeks, MD, PhD

September 4th 2026

What the Efficacy Data from KEYNOTE-B15/EV-304 Revealed

ByJoshua J. Meeks, MD, PhD

September 4th 2026

Latest CME

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Trending on Urology Times

Managing BPH Before Prostate Radiotherapy: Options Compared

Patient Selection and Partnership in Prostate Radiotherapy Spacing

The role of diet and lifestyle in prostate cancer care, with Lorelei A. Mucci, ScD, MPH

Alternative BCG strains may help address ongoing supply challenges in NMIBC

Doublet or triplet? Urologists weighs in on mCSPC options